person · Reporting owner

Sandor Victor

Disclosed activity across 6 companies

Tapewire entity: 31980
SEC CIK: 0001620368

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ADC Therapeutics SAADCT · Entity 6502	Director	June 01, 2026	June 03, 2026
AbCellera Biologics Inc.ABCL · Entity 4118	Director	July 01, 2026	July 06, 2026
Kymera Therapeutics, Inc.KYMR · Entity 3545	Director	June 24, 2026	June 25, 2026
Prelude Therapeutics IncPRLD · Entity 5561	Director	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADC Therapeutics SA

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	140,686	Ending reported balance After 2026-06-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-01 · Grant · Acquired 45,000 · Balance 153,286 F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-03 · Tax withholding · Disposed 12,600 · Balance 140,686 F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

AbCellera Biologics Inc.

Report date July 01, 2026 · Filed July 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.85 · Expires 2036-07-01	Direct	152,207	Reported balance After 2026-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-01 · Grant · Acquired 152,207 · Balance 152,207 F1: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on July 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on July 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Kymera Therapeutics, Inc.

Report date June 24, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23	Direct	6,068	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Prelude Therapeutics Inc

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08	Direct	38,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARRAY BIOPHARMA INC

Report date July 30, 2019 · Filed July 30, 2019

Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-07-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-30 · Disposition to issuer · Disposed 209,543 · Balance 114,821 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 114,821 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2025-04-01	Direct	Reported balance After 2019-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-30 · Disposition to issuer · Disposed 87,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on April 1, 2016.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-01	Direct	Reported balance After 2019-07-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-07-30 · Disposition to issuer · Disposed 187,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on April 1, 2017.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2026-12-27	Direct	Reported balance After 2019-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-07-30 · Disposition to issuer · Disposed 270,828 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on December 26, 2017.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.92 · Expires 2027-12-16	Direct	Reported balance After 2019-07-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-07-30 · Disposition to issuer · Disposed 289,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8: The option provided for vesting in four equal annual installments beginning on December 16, 2018.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.97 · Expires 2028-12-16	Direct	Reported balance After 2019-07-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-07-30 · Disposition to issuer · Disposed 289,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9: The option provided for vesting in four equal annual installments beginning on December 16, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.

F4: The option provided for vesting in four equal annual installments beginning on April 1, 2016.

F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F6: The option provided for vesting in four equal annual installments beginning on April 1, 2017.

F7: The option provided for vesting in four equal annual installments beginning on December 26, 2017.

F8: The option provided for vesting in four equal annual installments beginning on December 16, 2018.

F9: The option provided for vesting in four equal annual installments beginning on December 16, 2019.

Merus N.V.

Report date December 12, 2025 · Filed December 12, 2025

Section 16 reporting ended · disclosed 2025-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.60 · Expires 2035-05-22	Direct	Reported balance After 2025-12-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-12-12 · Disposition to issuer · Disposed 13,193 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.73 · Expires 2034-05-07	Direct	Reported balance After 2025-12-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-12 · Disposition to issuer · Disposed 8,844 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2033-06-08	Direct	Reported balance After 2025-12-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-12 · Disposition to issuer · Disposed 14,414 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2032-05-31	Direct	Reported balance After 2025-12-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-12 · Disposition to issuer · Disposed 16,604 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-05-28	Direct	Reported balance After 2025-12-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-12 · Disposition to issuer · Disposed 6,120 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.09 · Expires 2030-06-30	Direct	Reported balance After 2025-12-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-12 · Disposition to issuer · Disposed 8,631 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.39 · Expires 2029-01-10	Direct	Reported balance After 2025-12-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-12 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Filing footnotes · ownership attribution and instrument terms

F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 30, 2019 Filed Jun 3, 2019 16:03 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	15,728	$3.65	$57,407.20	Disclosure SEC source: 0001562180-19-003220 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 28, 2019 Filed May 28, 2019 16:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Options (Right to buy) · Derivative	46,766	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001562180-19-003124 · primarydocument.xml · derivative · entry 6 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,862 Underlying: Common Stock · 46,766 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on September 22, 2015. Read SEC document
May 28, 2019 Filed May 28, 2019 16:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	74,915	$27.00	$2,022,929.75	Disclosure SEC source: 0001562180-19-003124 · primarydocument.xml · nonDerivative · entry 4 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,543 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $26.75 to $27.10. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
May 28, 2019 Filed May 28, 2019 16:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	46,766	$3.65	$170,695.90	Disclosure SEC source: 0001562180-19-003124 · primarydocument.xml · nonDerivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 23, 2019 Filed May 28, 2019 16:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	40,634	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001562180-19-003124 · primarydocument.xml · derivative · entry 5 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,628 Underlying: Common Stock · 40,634 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on September 22, 2015. Read SEC document
May 23, 2019 Filed May 28, 2019 16:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	40,634	$26.50	$1,076,845.70	Disclosure SEC source: 0001562180-19-003124 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,692 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $26.50 to $26.51. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
May 23, 2019 Filed May 28, 2019 16:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	40,634	$3.65	$148,314.10	Disclosure SEC source: 0001562180-19-003124 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2019 Filed May 23, 2019 17:26 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	12,600	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001562180-19-003078 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,262 Underlying: Common Stock · 12,600 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on September 22, 2015. Read SEC document
May 21, 2019 Filed May 23, 2019 17:26 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	12,600	$26.50	$333,900.00	Disclosure SEC source: 0001562180-19-003078 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,692 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 21, 2019 Filed May 23, 2019 17:26 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	12,600	$3.65	$45,990.00	Disclosure SEC source: 0001562180-19-003078 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	7,813	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-19-002181 · primarydocument.xml · derivative · entry 4 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,813 Underlying: Common Stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016. F4 · derivative.expiration_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	7,813	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-19-002181 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015. F3 · derivative.expiration_date: The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	6,932	$24.60	$170,527.20	Disclosure SEC source: 0001562180-19-002181 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,692 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:30 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	15,626	$0.00	$0.00	Disclosure SEC source: 0001562180-19-002181 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on April 1, 2015 and April 1, 2016 as a result of the vesting of one fourth of such RSUs. Read SEC document
December 27, 2018 Filed Jan 2, 2019 16:32 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	6,268	$14.05	$88,091.10	Disclosure SEC source: 0001562180-19-000071 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,998 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $14.00 to $14.25. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	12,062	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005031 · primarydocument.xml · derivative · entry 6 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,188 Underlying: Common Stock · 12,062 shares Expires 2021-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	11,284	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005031 · primarydocument.xml · derivative · entry 5 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,570 Underlying: Common Stock · 11,284 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	10,378	$15.97	$165,736.66	Disclosure SEC source: 0001562180-18-005031 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,266 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	23,346	$0.00	$0.00	Disclosure SEC source: 0001562180-18-005031 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs. Read SEC document
December 14, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantStock Option (Right to Buy) · Derivative	289,500	$0.00 Strike: $15.97	$0.00	Disclosure SEC source: 0001562180-18-005031 · primarydocument.xml · derivative · entry 4 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,500 Underlying: Common Stock · 289,500 shares Expires 2028-12-16 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning on December 16, 2019. Read SEC document
December 14, 2018 Filed Dec 18, 2018 19:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantRestricted Stock Units · Derivative	48,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005031 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,250 Underlying: Common Stock · 48,250 shares Expires 2022-12-20 F3 · derivative.exercise_date: RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019. Read SEC document
December 03, 2018 Filed Dec 6, 2018 16:02 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	127,397	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001562180-18-004844 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,862 Underlying: Common Stock · 127,397 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on September 22, 2015. Read SEC document
December 03, 2018 Filed Dec 6, 2018 16:02 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	115,185	$16.21	$1,867,045.18	Disclosure SEC source: 0001562180-18-004844 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,298 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $16.00 to $16.435. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
December 03, 2018 Filed Dec 6, 2018 16:02 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	127,397	$3.65	$464,999.05	Disclosure SEC source: 0001562180-18-004844 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 04, 2018 Filed Sep 5, 2018 16:18 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	9,687	$15.38	$148,937.63	Disclosure SEC source: 0001562180-18-003834 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,086 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $15.37 to $15.38. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:21 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	17,440	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-003128 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,440 shares Expires 2018-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: RSUs representing 17,440 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:21 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	7,753	$18.50	$143,430.50	Disclosure SEC source: 0001562180-18-003128 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,773 F2 · kind: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:21 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	17,440	$0.00	$0.00	Disclosure SEC source: 0001562180-18-003128 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II. Read SEC document
June 19, 2018 Filed Jun 21, 2018 16:20 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	77,576	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001562180-18-003074 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,259 Underlying: Common Stock · 77,576 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on September 22, 2015. Read SEC document
June 19, 2018 Filed Jun 21, 2018 16:20 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	77,576	$18.76	$1,455,325.76	Disclosure SEC source: 0001562180-18-003074 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,086 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $18.75 to $18.845. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
June 19, 2018 Filed Jun 21, 2018 16:20 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	77,576	$3.65	$283,152.40	Disclosure SEC source: 0001562180-18-003074 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2018 Filed Jun 15, 2018 16:25 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	22,424	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001562180-18-003024 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,835 Underlying: Common Stock · 22,424 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on September 22, 2015. Read SEC document
June 13, 2018 Filed Jun 15, 2018 16:25 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	22,424	$18.75	$420,450.00	Disclosure SEC source: 0001562180-18-003024 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,086 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 13, 2018 Filed Jun 15, 2018 16:25 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	22,424	$3.65	$81,847.60	Disclosure SEC source: 0001562180-18-003024 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 03, 2018 Filed Apr 3, 2018 18:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	8,689	$15.35	$133,376.15	Disclosure SEC source: 0001562180-18-001804 · primarydocument.xml · nonDerivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,086 F4 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
April 01, 2018 Filed Apr 3, 2018 18:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	7,812	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-001804 · primarydocument.xml · derivative · entry 4 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,626 Underlying: Common Stock · 7,812 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The remaining RSUs vest and will be settled in stock in two equal annual installments on April 1, 2019 and 2020. Read SEC document
April 01, 2018 Filed Apr 3, 2018 18:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	6,936	$16.32	$113,195.52	Disclosure SEC source: 0001562180-18-001804 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,775 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person. Read SEC document
April 01, 2018 Filed Apr 3, 2018 18:49 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	7,812	$0.00	$0.00	Disclosure SEC source: 0001562180-18-001804 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on April 1, 2016 as a result of the vesting of one fourth of such RSUs. F2 · balance_after: Includes (i) 7,813 unvested Restricted Stock Units ("RSUs") awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and (ii) 7,813 shares of common stock issued upon the vesting of these RSU's on April 1, 2018. Read SEC document
March 09, 2018 Filed Mar 9, 2018 17:42 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	182,191	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001562180-18-001592 · primarydocument.xml · derivative · entry 4 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,259 Underlying: Common Stock · 182,191 shares Expires 2024-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on September 22, 2015. Read SEC document
March 09, 2018 Filed Mar 9, 2018 17:42 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	111,518	$17.72	$1,976,098.96	Disclosure SEC source: 0001562180-18-001592 · primarydocument.xml · nonDerivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,899 F2 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
March 09, 2018 Filed Mar 9, 2018 17:42 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	44,498	$17.70	$787,614.60	Disclosure SEC source: 0001562180-18-001592 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,417 F2 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
March 09, 2018 Filed Mar 9, 2018 17:42 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	182,191	$3.65	$664,997.15	Disclosure SEC source: 0001562180-18-001592 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,625 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantStock Option (Right to Buy) · Derivative	289,500	$0.00 Strike: $10.92	$0.00	Disclosure SEC source: 0001562180-17-003954 · primarydocument.xml · derivative · entry 5 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,500 Underlying: Common Stock · 289,500 shares Expires 2027-12-16 F8 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2018. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantRestricted Stock Units · Derivative	48,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-17-003954 · primarydocument.xml · derivative · entry 4 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,250 Underlying: Common Stock · 48,250 shares Expires 2021-12-17 F7 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	11,284	$0.00	$0.00	Disclosure SEC source: 0001562180-17-003954 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,854 Underlying: Common Stock · 11,284 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: RSUs were awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. F5 · derivative.exercise_date: The RSUs vested on December 16, 2017. F6 · balance_after: Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	5,310	$10.92	$57,985.20	Disclosure SEC source: 0001562180-17-003954 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,724 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:04 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	11,284	$8.79	$99,186.36	Disclosure SEC source: 0001562180-17-003954 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs. F2 · balance_after: Includes 15,625 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
April 01, 2017 Filed Apr 4, 2017 21:43 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	7,812	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-17-001466 · primarydocument.xml · derivative · entry 3 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,438 Underlying: Common Stock · 7,812 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2017. F5 · balance_after: Consists of unvested RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person. Read SEC document
April 01, 2017 Filed Apr 4, 2017 21:43 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	5,022	$8.94	$44,896.68	Disclosure SEC source: 0001562180-17-001466 · primarydocument.xml · nonDerivative · entry 2 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,406 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person. Read SEC document
April 01, 2017 Filed Apr 4, 2017 21:43 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	7,812	$0.00	$0.00	Disclosure SEC source: 0001562180-17-001466 · primarydocument.xml · nonDerivative · entry 1 Sandor Victor · CIK 0001620368 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued on settlement of Restricted Stock Units ("RSUs") granted to the reporting person, of which 2,528 shares were withheld upon vesting to satisfy tax withholding obligations. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. F2 · balance_after: Includes 15,626 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.